Development of a multiplex methylation specific PCR suitable for (early) detection of non-small cell lung cancer

Epigenetics

Volumn 9, Issue 8, 2014, Pages 1138-1148

  Nawaz, Imran ^a,b   Qiu, Xiaoming ^c   Wu, Heng ^c   Li, Yang ^c   Fan, Yaguang ^c   Hu, Li Fu ^a   Zhou, Qinghua ^c   Ernberg, Ingemar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF BALOCHISTAN   (Pakistan)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Bisulfite treatment; DNA methylation; Expression microarray; Lung cancer; Methylation microarray; MMSP; NSCLC; PCR

Indexed keywords

ALPHA CALCITONIN GENE RELATED PEPTIDE; METHYL CPG BINDING PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR PITX2; TRANSCRIPTION FACTOR TBX5; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; CALCA GENE; CONTROLLED STUDY; CPG ISLAND; DLEC1 GENE; DNA EXTRACTION; DNA METHYLATION; DNA MICROARRAY; EARLY DIAGNOSIS; FEMALE; HOXA9 GENE; HUMAN; HUMAN TISSUE; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MULTIPLEX METHYLATION SPECIFIC POLYMERASE CHAIN REACTION ASSAY; MULTIPLEX POLYMERASE CHAIN REACTION; PITX2 GENE; RASSF1A GENE; SENSITIVITY AND SPECIFICITY; TBX5 GENE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; EARLY DETECTION OF CANCER; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84905655774     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.29499     Document Type: Article

References (85)

1. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of Lung Cancer. Semin Intervent Radiol 2013; 30:93-8; PMID:24436524; http:// dx.doi.org/10.1055/s-0033-1342949
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http:// dx.doi.org/10.3322/caac.20107
3. Wang YC, Wei LJ, Liu JT, Li SX, Wang QS. Comparison of Cancer Incidence between China and the USA. Cancer Biol Med 2012; 9:128-32; PMID:23691468
4. Chen W, Zhang S, Zou X. [Estimation and projection of lung cancer incidence and mortality in China]. Zhongguo Fei Ai Za Zhi 2010; 13:488-93; PMID:20677647
5. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, He J. The incidences and mortalities of major cancers in China, 2009. Chin J Cancer 2013; 32:106-12; PMID:23452393; http://dx.doi.org/10.5732/ cjc.013.10018
6. Chen WQ, Zhang SW, Zou XN, Zhao P. [An analysis of lung cancer mortality in China, 2004-2005]. Zhonghua yu fang yi xue za zhi. Chin J Prev Med 2010; 44:378-82
7. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001; 18:1059-68; PMID:11829087; http://dx.doi.org/10.1183/09031936.01.00275301
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108; PMID:15761078; http://dx.doi.org/10.3322/ canjclin.55.2.74
9. Lokk K, Vooder T, Kolde R, Välk K, Võsa U, Roosipuu R, Milani L, Fischer K, Koltsina M, Urgard E, et al. Methylation markers of earlystage non-small cell lung cancer. PLoS One 2012; 7:e39813; PMID:22768131; http://dx.doi. org/10.1371/journal.pone.0039813
10. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of 4 chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8; PMID:11784875; http://dx.doi. org/10.1056/NEJMoa011954
11. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8:286-98; PMID:17339880; http://dx.doi. org/10.1038/nrg2005
12. Singal R, Ginder GD. DNA methylation. Blood 1999; 93:4059-70; PMID:10361102
13. Walter K, Holcomb T, Januario T, Yauch RL, Du P, Bourgon R, Seshagiri S, Amler LC, Hampton GM, Shames D. Discovery and development of DNA methylation-based biomarkers for lung cancer. Epigenomics 2014; 6:59-72; PMID:24579947; http://dx.doi.org/10.2217/epi.13.81
14. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 2013; 5:69ra10; PMID:23345608; http://dx.doi.org/10.1126/scitranslmed.3005211
15. Li LL, Shu XS, Wang ZH, Cao Y, Tao Q. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin J Cancer 2011; 30:231-9; PMID:21439244; http://dx.doi.org/10.5732/ cjc.011.10080
16. Suvà ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013; 339:1567-70; PMID:23539597; http://dx.doi.org/10.1126/ science.1230184
17. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7:21-33; PMID:16369569; http://dx.doi. org/10.1038/nrg1748
18. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4:707-17; PMID:15343277; http://dx.doi. org/10.1038/nrc1432
19. Lee SM, Park JY, Kim DS. Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation. Mol Cells 2013; 36:69-73; PMID:23686431; http://dx.doi.org/10.1007/ s10059-013-0060-7
20. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12:451-62; PMID:12450731; http://dx.doi. org/10.1016/S1044579X02000883
21. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61:249-55; PMID:11196170
22. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002; 21:5450-61; PMID:12154407; http://dx.doi.org/10.1038/ sj.onc.1205605
23. Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 2005; 26:1481-7; PMID:15661809; http://dx.doi.org/10.1093/carcin/ bgi020
24. Zhang X, Li W, Li H, Ma Y, He G, Tan G. Genomic methylation profiling combined with gene expression microarray reveals the aberrant methylation mechanism involved in nasopharyngeal carcinoma taxol resistance. Anticancer Drugs 2012; 23:856-64; PMID:22824824; http://dx.doi.org/10.1097/ CAD.0b013e3283548d73
25. Fujii M, Fujimoto N, Hiraki A, Gemba K, Aoe K, Umemura S, Katayama H, Takigawa N, Kiura K, Tanimoto M, et al. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma. Cancer Sci 2012; 103:510-4; PMID:22146010; http://dx.doi. org/10.1111/j.1349-7006.2011.02180.x
26. Kneip C, Schmidt B, Seegebarth A, Weickmann S, Fleischhacker M, Liebenberg V, Field JK, Dietrich D. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol 2011; 6:1632-8; PMID:21694641; http://dx.doi. org/10.1097/JTO.0b013e318220ef9a
27. Schmidt B, Liebenberg V, Dietrich D, Schlegel T, Kneip C, Seegebarth A, Flemming N, Seemann S, Distler J, Lewin J, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 2010; 10:600; PMID:21047392; http://dx.doi. org/10.1186/1471-2407-10-600
28. Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD, Pfeifer GP. DNA methylation biomarkers for lung cancer. Tumour Biol 2012; 33:287-96; PMID:22143938; http://dx.doi.org/10.1007/s13277-011-0282-2
29. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60:5954-8; PMID:11085511
30. Dahl C, Guldberg P. DNA methylation analysis techniques. Biogerontology 2003; 4:233-50; PMID:14501188; http://dx.doi. org/10.1023/A:1025103319328
31. Shames DS, Minna JD, Gazdar AF. Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett 2007; 251:187-98; PMID:17166656; http://dx.doi.org/10.1016/j.canlet.2006.10.014
32. Shen L, Waterland RA. Methods of DNA methylation analysis. Curr Opin Clin Nutr Metab Care 2007; 10:576-81; PMID:17693740; http://dx.doi. org/10.1097/MCO.0b013e3282bf6f43
33. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93:9821-6; PMID:8790415; http://dx.doi.org/10.1073/pnas.93.18.9821
34. Zhang Z, Sun D, Hutajulu SH, Nawaz I, Nguyen Van D, Huang G, Haryana SM, Middeldorp JM, Ernberg I, Hu LF. Development of a non-invasive method, multiplex methylation specific PCR (MMSP), for early diagnosis of nasopharyngeal carcinoma. PLoS One 2012; 7:e45908; PMID:23144779; http://dx.doi. org/10.1371/journal.pone.0045908
35. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-9; PMID:11309270
36. Figueroa ME, Reimers M, Thompson RF, Ye K, Li Y, Selzer RR, Fridriksson J, Paietta E, Wiernik P, Green RD, et al. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One 2008; 3:e1882; PMID:18365023; http:// dx.doi.org/10.1371/journal.pone.0001882
37. Marchevsky AM, Tsou JA, Laird-Offringa IA. Classification of individual lung cancer cell lines based on DNA methylation markers: use of linear discriminant analysis and artificial neural networks. J Mol Diagn 2004; 6:28-36; PMID:14736824; http:// dx.doi.org/10.1016/S1525-1578(10)60488-6
38. Sato T, Arai E, Kohno T, Tsuta K, Watanabe S, Soejima K, Betsuyaku T, Kanai Y. DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma. PLoS One 2013; 8:e59444; PMID:23544068; http://dx.doi.org/10.1371/journal. pone.0059444
39. Gehring WJ, Hiromi Y. Homeotic genes and the homeobox. Annu Rev Genet 1986; 20:147-73; PMID:2880555; http://dx.doi.org/10.1146/annurev. ge.20.120186.001051
40. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439:871-4; PMID:16357870; http://dx.doi. org/10.1038/nature04431
41. Hwang SH, Kim KU, Kim JE, Kim HH, Lee MK, Lee CH, Lee SY, Oh T, An S. Detection of HOXA9 gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients. Clin Chem Lab Med 2011; 49:699-704; PMID:21480815; http:// dx.doi.org/10.1515/CCLM.2011.108
42. Son JW, Jeong KJ, Jean WS, Park SY, Jheon S, Cho HM, Park CG, Lee HY, Kang J. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients. Cancer Lett 2011; 311:29-37; PMID:21757291; http://dx.doi.org/10.1016/j. canlet.2011.06.021
43. He ML, Chen Y, Peng Y, Jin D, Du D, Wu J, Lu P, Lin MC, Kung HF. Induction of apoptosis and inhibition of cell growth by developmental regulator hTBX5. Biochem Biophys Res Commun 2002; 297:185-92; PMID:12237100; http://dx.doi.org/10.1016/ S0006-291X(02)02142-3
44. Maitra M, Schluterman MK, Nichols HA, Richardson JA, Lo CW, Srivastava D, Garg V. Interaction of Gata4 and Gata6 with Tbx5 is critical for normal cardiac development. Dev Biol 2009; 326:368-77; PMID:19084512; http://dx.doi.org/10.1016/j. ydbio.2008.11.004
45. Mori AD, Zhu Y, Vahora I, Nieman B, Koshiba-Takeuchi K, Davidson L, Pizard A, Seidman JG, Seidman CE, Chen XJ, et al. Tbx5-dependent rheostatic control of cardiac gene expression and morphogenesis. Dev Biol 2006; 297:566-86; PMID:16870172; http://dx.doi.org/10.1016/j.ydbio.2006.05.023
46. Plageman TF Jr., Yutzey KE. Microarray analysis of Tbx5-induced genes expressed in the developing heart. Dev Dyn 2006; 235:2868-80; PMID:16894625; http://dx.doi.org/10.1002/dvdy.20923
47. Yu J, Ma X, Cheung KF, Li X, Tian L, Wang S, Wu CW, Wu WK, He M, Wang M, et al. Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer. Oncogene 2010; 29:6464-74; PMID:20802524; http://dx.doi.org/10.1038/onc.2010.370
48. Martin DM, Skidmore JM, Fox SE, Gage PJ, Camper SA. Pitx2 distinguishes subtypes of terminally differentiated neurons in the developing mouse neuroepithelium. Dev Biol 2002; 252:84-99; PMID:12453462; http://dx.doi.org/10.1006/dbio.2002.0835
49. Martin DM, Skidmore JM, Philips ST, Vieira C, Gage PJ, Condie BG, Raphael Y, Martinez S, Camper SA. PITX2 is required for normal development of neurons in the mouse subthalamic nucleus and midbrain. Dev Biol 2004; 267:93-108; PMID:14975719; http:// dx.doi.org/10.1016/j.ydbio.2003.10.035
50. Dietrich D, Hasinger O, Liebenberg V, Field JK, Kristiansen G, Soltermann A. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol 2012; 21:93-104; PMID:22555092; http://dx.doi.org/10.1097/PDM.0b013e318240503b
51. Dong YL, Reddy DM, Green KE, Chauhan MS, Wang HQ, Nagamani M, Hankins GDV, Yallampalli C. Calcitonin gene-related peptide (CALCA) is a proangiogenic growth factor in the human placental development. Biol Reprod 2007; 76:892-9; PMID:17267696; http://dx.doi.org/10.1095/biolreprod.106.059089
52. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 1996; 17:533-85; PMID:8897024; http://dx.doi. org/10.1210/edrv-17-5-533
53. Segond N, Gerbaud P, Taboulet J, Jullienne A, Moukhtar MS, Evain-Brion D. Retinoic acid abolishes the calcitonin gene-related peptide autocrine system in F9 teratocarcinoma cells. J Cell Biochem 1997; 64:447-57; PMID:9057102; http://dx.doi.org/10.1002/ (SICI)1097-4644(19970301)64:3<447::AIDJCB11> 3.0.CO;2-D
54. Nagakawa O, Ogasawara M, Murata J, Fuse H, Saiki I. Effect of prostatic neuropeptides on migration of prostate cancer cell lines. Int J Urol 2001; 8:65-70; PMID:11240828; http://dx.doi. org/10.1046/j.1442-2042.2001.00250.x
55. Sung CP, Arleth AJ, Aiyar N, Bhatnagar PK, Lysko PG, Feuerstein G. CGRP stimulates the adhesion of leukocytes to vascular endothelial cells. Peptides 1992; 13:429-34; PMID:1326102; http://dx.doi. org/10.1016/0196-9781(92)90071-A
56. Ji M, Guan H, Gao C, Shi B, Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011; 11:147; PMID:21507233; http://dx.doi. org/10.1186/1471-2407-11-147
57. Morán A, Fernández-Marcelo T, Carro J, De Juan C, Pascua I, Head J, Gómez A, Hernando F, Torres AJ, Benito M, et al. Methylation profiling in non-small cell lung cancer: clinical implications. Int J Oncol 2012; 40:739-46; PMID:22076605
58. Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C, Liu L, Tommasi S, Pfeifer GP. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 2003; 18:665-77; PMID:12647816
59. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000; 60:6116-33; PMID:11085536
60. Amin KS, Banerjee PP. The cellular functions of RASSF1A and its inactivation in prostate cancer. J Carcinog 2012; 11:3; PMID:22438769; http://dx.doi. org/10.4103/1477-3163.93000
61. Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 2002; 8:2362-8; PMID:12114441
62. Vos MD, Martinez A, Elam C, Dallol A, Taylor BJ, Latif F, Clark GJ. A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res 2004; 64:4244-50; PMID:15205337; http://dx.doi.org/10.1158/0008-5472.CAN-04-0339
63. Choi N, Son DS, Song I, Lee HS, Lim YS, Song MS, Lim DS, Lee J, Kim H, Kim J. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer. Int J Cancer 2005; 115:575-81; PMID:15700308; http://dx.doi. org/10.1002/ijc.20916
64. Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y. Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients. Oncol Lett 2010; 1:283-7; PMID:22966295; http:// dx.doi.org/10.3892/ol_00000050
65. Seng TJ, Currey N, Cooper WA, Lee CS, Chan C, Horvath L, Sutherland RL, Kennedy C, McCaughan B, Kohonen-Corish MR. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 2008; 99:375-82; PMID:18594535; http://dx.doi. org/10.1038/sj.bjc.6604452
66. Song H, Yi J, Zhang Y, Wang R, Chen L. [DNA methylation of tumor suppressor genes located on chromosome 3p in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2011; 14:233-8; PMID:21426665
67. Stebbing J, Bower M, Syed N, Smith P, Yu V, Crook T. Epigenetics: an emerging technology in the diagnosis and treatment of cancer. Pharmacogenomics 2006; 7:747-57; PMID:16886899; http://dx.doi. org/10.2217/14622416.7.5.747
68. Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 1996; 24:5064-6; PMID:9016686; http://dx.doi.org/10.1093/ nar/24.24.5064
69. Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44-57; PMID:19131956; http://dx.doi.org/10.1038/ nprot.2008.211
70. Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37:1-13; PMID:19033363; http://dx.doi. org/10.1093/nar/gkn923
71. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res 2012; 22:1197-211; PMID:22613842; http://dx.doi.org/10.1101/ gr.132662.111
72. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, Farinas AJ, Milchgrub S, Euhus DM, Gilcrease M, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001; 7:1998-2004; PMID:11448917
73. Machida EO, Brock MV, Hooker CM, Nakayama J, Ishida A, Amano J, Picchi MA, Belinsky SA, Herman JG, Taniguchi S, et al. Hypermethylation of ASC/ TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 2006; 66:6210-8; PMID:16778195; http://dx.doi.org/10.1158/0008-5472.CAN-05-4447
74. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006; 3:e486; PMID:17194187; http://dx.doi.org/10.1371/ journal.pmed.0030486
75. Feng Q, Hawes SE, Stern JE, Wiens L, Lu H, Dong ZM, Jordan CD, Kiviat NB, Vesselle H. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2008; 17:645-54; PMID:18349282; http://dx.doi.org/10.1158/1055-9965.EPI-07-2518
76. Xiao X, Zhao W, Tian F, Zhou X, Zhang J, Huang T, Hou B, Du C, Wang S, Mo Y, et al. Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma. Tumour Biol 2014; 35:3755-63; PMID:24338690; http://dx.doi. org/10.1007/s13277-013-1497-1
77. Anglim PP, Galler JS, Koss MN, Hagen JA, Turla S, Campan M, Weisenberger DJ, Laird PW, Siegmund KD, Laird-Offringa IA. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer 2008; 7:62; PMID:18616821; http://dx.doi. org/10.1186/1476-4598-7-62
78. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, Kernstine KH, Riggs AD, Pfeifer GP. Homeobox gene methylation in lung cancer studied by genomewide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A 2007; 104:5527-32; PMID:17369352; http://dx.doi. org/10.1073/pnas.0701059104
79. Nelson HH, Marsit CJ, Christensen BC, Houseman EA, Kontic M, Wiemels JL, Karagas MR, Wrensch MR, Zheng S, Wiencke JK, et al. Key epigenetic changes associated with lung cancer development: results from dense methylation array profiling. Epigenetics 2012; 7:559-66; PMID:22522909; http:// dx.doi.org/10.4161/epi.20219
80. Dmitriev AA, Kashuba VI, Haraldson K, Senchenko VN, Pavlova TV, Kudryavtseva AV, Anedchenko EA, Krasnov GS, Pronina IV, Loginov VI, et al. Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics 2012; 7:502-13; PMID:22491060; http://dx.doi.org/10.4161/ epi.19801
81. Planque C, Aïnciburu M, Heuzé-Vourc'h N, Régina S, de Monte M, Courty Y. Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues. Biol Chem 2006; 387:783-8; PMID:16800740; http://dx.doi. org/10.1515/BC.2006.098
82. Zhang Y, Song H, Miao Y, Wang R, Chen L. Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci 2010; 101:934-40; PMID:20180809; http://dx.doi. org/10.1111/j.1349-7006.2009.01486.x
83. Heller G, Fong KM, Girard L, Seidl S, End-Pfützenreuter A, Lang G, Gazdar AF, Minna JD, Zielinski CC, Zöchbauer-Müller S. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 2006; 25:959-68; PMID:16205641; http://dx.doi.org/10.1038/ sj.onc.1209115
84. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18:1427-31; PMID:12424112; http://dx.doi.org/10.1093/ bioinformatics/18.11.1427
85. Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ, Huang DP. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001; 61:3877-81; PMID:11358799